Notice for tocilizumab (Roche Products Pty Limited)
Active ingredients
tocilizumab
Sponsor
Date of review outcome
Lapse date
Type
Provisional approval
Indication
Coronavirus disease 2019 (COVID-19) (IV formulation only) for the treatment of coronavirus disease 2019 (COVID-19) in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation
Therapeutic area
Infectious diseases